PMC:7275137 / 14-315 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":3,"end":11},"obj":"Body_part"},{"id":"T2","span":{"begin":100,"end":108},"obj":"Body_part"},{"id":"T3","span":{"begin":196,"end":204},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma63836"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma63836"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma63836"}],"text":"le lysosome targeting agents should be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication • Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":75,"end":83},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"le lysosome targeting agents should be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication • Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":3,"end":11},"obj":"http://purl.obolibrary.org/obo/GO_0005764"},{"id":"T2","span":{"begin":100,"end":108},"obj":"http://purl.obolibrary.org/obo/GO_0005764"},{"id":"T3","span":{"begin":196,"end":204},"obj":"http://purl.obolibrary.org/obo/GO_0005764"}],"text":"le lysosome targeting agents should be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication • Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":241,"end":246},"obj":"Chemical"},{"id":"T2","span":{"begin":269,"end":284},"obj":"Chemical"},{"id":"T3","span":{"begin":269,"end":278},"obj":"Chemical"},{"id":"T4","span":{"begin":279,"end":284},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"le lysosome targeting agents should be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication • Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":167,"end":192},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T2","span":{"begin":175,"end":192},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T3","span":{"begin":175,"end":192},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"le lysosome targeting agents should be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication • Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute"}

{"project":"LitCovid-sentences","denotations":[{"id":"T2","span":{"begin":86,"end":96},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"le lysosome targeting agents should be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication • Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":75,"end":83},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"le lysosome targeting agents should be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication • Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute"}